• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by JP Morgan Chase & Co.

    7/7/25 12:57:34 PM ET
    $JPM
    Major Banks
    Finance
    Get the next $JPM alert in real time by email
    FWP 1 jpm_fwp-20329.htm SUMMARY TERMS

    JPMorgan Chase Financial Company LLC

    Free Writing Prospectus Filed Pursuant to Rule 433

    Registration Statement Nos. 333-270004 and 333-270004-01

    Dated July 7, 2025

    3yrNC6m NDX/SPX/SX5E Contingent Income Auto-Callable Securities

    This document provides a summary of the terms of the securities. Investors must carefully review the accompanying preliminary pricing supplement referenced below, product supplement, underlying supplement, prospectus supplement, prospectus and prospectus addendum and the “Risk Considerations” on the following page, prior to making an investment decision.

     


    SUMMARY TERMS

    Issuer:

    JPMorgan Chase Financial Company LLC (“JPMorgan Financial”)

    Guarantor:

    JPMorgan Chase & Co.

    Underlying indices:

    Nasdaq-100 Index® (Bloomberg ticker: NDX Index) (the “NDX Index”), S&P 500® Index (Bloomberg ticker: SPX Index) (the “SPX Index”) and EURO STOXX 50® Index (Bloomberg ticker: SX5E Index) (the “SX5E Index”) (each, an “underlying index”)

    Early redemption:

    If, on any of the determination dates (other than the first and final determination dates), the closing level of each underlying index is greater than or equal to its initial index value, the securities will be automatically redeemed for an early redemption payment on the first contingent payment date immediately following the related determination date. No further payments will be made on the securities once they have been redeemed.

    The securities will not be redeemed early on any contingent payment date if the closing level of any underlying index is below its initial index value on the related determination date.

    Early redemption payment:

    The early redemption payment will be an amount equal to (i) the stated principal amount plus (ii) any contingent quarterly payment otherwise due with respect to the related quarterly monitoring period.

    Contingent quarterly payment:

    ●If the closing level of each underlying index is greater than or equal to its coupon barrier level on each day during a quarterly monitoring period, we will pay a contingent quarterly payment of at least $22.125 (at least 2.2125% of the stated principal amount) per security on the related contingent payment date. The actual contingent quarterly payment will be provided in the pricing supplement.

    ●If the closing level of any underlying index is less than its coupon barrier level on any day during a quarterly monitoring period, no contingent quarterly payment will be payable with respect to that quarterly monitoring period. It is possible that the closing level of one or more of the underlying indices will be below their respective coupon barrier levels on at least one day during most or all of the quarterly monitoring periods so that you will receive few or no contingent quarterly payments.

    Payment at maturity:

    ●If the final index value of each underlying index is greater than or equal to its downside threshold level:

    (i) the stated principal amount plus, (ii) if the closing level of each underlying index on each day during the final quarterly monitoring period is greater than or equal to its coupon barrier level, the contingent quarterly payment with respect to the final quarterly monitoring period

     

    ●If the final index value of any underlying index is less than its downside threshold level:

    (i) the stated principal amount times (ii) the index performance factor of the worst performing underlying index. This cash payment will be less than 65% of the stated principal amount of the securities and could be zero.

    Coupon barrier level:

    With respect to each underlying index, 75% of its initial index value

    Downside threshold level:

    With respect to each underlying index, 65% of its initial index value

    Quarterly monitoring period:

    With respect to each contingent payment date, the period from but excluding the second immediately preceding determination date (or, in the case of the first determination date, from but excluding the pricing date) to and including the immediately preceding determination date

     

    Initial index value:

    With respect to each underlying index, its closing level on the pricing date

    Final index value:

    With respect to each underlying index, its closing level on the final determination date

    Worst performing underlying index:

    The underlying index with the worst index performance factor

    Index performance factor:

    With respect to each underlying index, its final index value divided by its initial index value

    Stated principal amount:

    $1,000 per security

    Issue price:

    $1,000 per security

    Pricing date:

    Expected to be July 8, 2025

    Original issue date (settlement date):

    3 business days after the pricing date

    Determination dates†:

    October 8, 2025, January 8, 2026, April 8, 2026, July 8, 2026, October 8, 2026, January 8, 2027, April 8, 2027, July 8, 2027, October 8, 2027, January 10, 2028, April 10, 2028 and July 10, 2028

    Contingent payment dates†:

    October 14, 2025, January 13, 2026, April 13, 2026, July 13, 2026, October 14, 2026, January 13, 2027, April 13, 2027, July 13, 2027, October 14, 2027, January 13, 2028, April 13, 2028 and the maturity date

    Maturity date†:

    July 13, 2028

    CUSIP / ISIN:

    48136FJZ6 / US48136FJZ62

    Preliminary pricing supplement:

    http://www.sec.gov/Archives/edgar/data/19617/000183988225037306/jpm_424b2-20286.htm

    †Subject to postponement or early acceleration

    The estimated value of the securities on the pricing date will be provided in the pricing supplement and will not be less than $930.00 per $1,000 stated principal amount security. For information about the estimated value of the securities, which likely will be lower than the price you paid for the securities, please see the hyperlink above.

    Any payment on the securities is subject to the credit risk of JPMorgan Financial, as issuer of the securities, and the credit risk of JPMorgan Chase & Co., as guarantor of the securities.

    Hypothetical Payout at Maturity

    Change in Worst Performing Underlying Index

    Payment at Maturity (excluding any contingent quarterly payment payable at maturity)

    50.00%

    $1,000.00

    40.00%

    $1,000.00

    30.00%

    $1,000.00

    20.00%

    $1,000.00

    10.00%

    $1,000.00

    5.00%

    $1,000.00

    0.00%

    $1,000.00

    -10.00%

    $1,000.00

    -20.00%

    $1,000.00

    -30.00%

    $1,000.00

    -35.00%

    $1,000.00

    -35.01%

    $649.90

    -40.00%

    $600.00

    -50.00%

    $500.00

    -60.00%

    $400.00

    -80.00%

    $200.00

    -100.00%

    $0.00


     

    JPMorgan Chase Financial Company LLC

    3yrNC6m NDX/SPX/SX5E Contingent Income Auto-Callable Securities

    Underlying Indices

    For more information about the underlying indices, including historical performance information, see the accompanying preliminary pricing supplement.

    Risk Considerations

    The risks identified below are not exhaustive. Please see “Risk Factors” in the accompanying prospectus supplement, product supplement and preliminary pricing supplement and Annex A to the accompanying prospectus addendum for additional information.

    Risks Relating to the Securities Generally

    ■The securities do not guarantee the return of any principal and your investment in the securities may result in a loss.

    ■You will not receive any contingent quarterly payment for any quarterly monitoring period if the closing level of any underlying index is less than its coupon barrier level on any day during that quarterly monitoring period.

    ■The contingent quarterly payment is based on the closing levels of the underlying indices during the quarterly monitoring periods.

    ■You are exposed to the price risk of all three underlying indices, with respect to all the contingent quarterly payments, if any, and the payment at maturity, if any.

    ■Because the securities are linked to the performance of the worst performing underlying index, you are exposed to greater risks of no contingent quarterly payments and sustaining a significant loss on your investment than if the securities were linked to just one underlying index.

    ■The securities are subject to the credit risks of JPMorgan Financial and JPMorgan Chase & Co., and any actual or anticipated changes to our or JPMorgan Chase & Co.’s credit ratings or credit spreads may adversely affect the market value of the securities.

    ■As a finance subsidiary, JPMorgan Financial has no independent operations and has limited assets.

    ■Investors will not participate in any appreciation of any underlying index.

    ■Early redemption risk.

    ■Secondary trading may be limited.

    ■We may accelerate your securities in our sole discretion and the calculation agent may adjust their final payment in good faith and in a commercially reasonable manner if a change-in-law event occurs.

    ■The final terms and estimated valuation of the securities will be provided in the pricing supplement.

    ■The U.S. federal income tax consequences of an investment in the securities are uncertain.

    Risks Relating to Conflicts of Interest

    ■Economic interests of the issuer, the guarantor, the calculation agent, the agent of the offering of the securities and other affiliates of the issuer may be different from those of investors.

    ■Hedging and trading activities by the issuer and its affiliates could potentially affect the value of the securities.

    Risks Relating to the Estimated Value and Secondary Market Prices of the Securities

    ■The estimated value of the securities will be lower than the original issue price (price to public) of the securities.

    ■The estimated value of the securities does not represent future values of the securities and may differ from others’ estimates.

    ■The estimated value of the securities is derived by reference to an internal funding rate.

    ■The value of the securities as published by J.P. Morgan Securities LLC (and which may be reflected on customer account statements) may be higher than the then-current estimated value of the securities for a limited time period.

    ■Secondary market prices of the securities will likely be lower than the original issue price of the securities.

    ■Secondary market prices of the securities will be impacted by many economic and market factors.

    Risks Relating to the Underlying Indices

    ■JPMorgan Chase & Co. is currently one of the companies that make up the SPX Index.

    ■Investing in the securities is not equivalent to investing in any underlying index.

    ■Adjustments to any underlying index could adversely affect the value of the securities.

    ■The securities are subject to risks associated with securities issued by non-U.S. companies with respect to the NDX Index and the SX5E Index.

    ■The securities are not directly exposed to fluctuations in foreign exchange rates with respect to the SX5E Index.

    ■Governmental legislative and regulatory actions, including sanctions, could adversely affect your investment in the securities.

    Tax Considerations

    You should review carefully the discussion in the accompanying preliminary pricing supplement under “Additional Information about the Securities — Tax considerations” concerning the U.S. federal income tax consequences of an investment in the securities, and you should consult your tax adviser.

    SEC Legend: JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. have filed a registration statement (including a prospectus) with the SEC for any offerings to which these materials relate. Before you invest, you should read the prospectus in that registration statement and the other documents relating to this offering that JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. has filed with the SEC for more complete information about JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. and this offering. You may get these documents without cost by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co., any agent or any dealer participating in the this offering will arrange to send you the prospectus and each prospectus supplement as well as any product supplement, underlying supplement and preliminary pricing supplement if you so request by calling toll-free 1-866-535-9248.

    Get the next $JPM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JPM

    DatePrice TargetRatingAnalyst
    7/8/2025$259.00Hold → Reduce
    HSBC Securities
    6/27/2025$235.00Neutral → Underperform
    Robert W. Baird
    5/15/2025$305.00Buy
    TD Cowen
    3/7/2025$215.00 → $220.00Underperform → Neutral
    Robert W. Baird
    1/3/2025$269.00Peer Perform → Outperform
    Wolfe Research
    11/20/2024Outperform → Perform
    Oppenheimer
    11/7/2024$200.00Neutral → Underperform
    Robert W. Baird
    9/30/2024$220.00 → $224.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $JPM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JPMorgan Chase downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded JPMorgan Chase from Hold to Reduce and set a new price target of $259.00

      7/8/25 8:30:31 AM ET
      $JPM
      Major Banks
      Finance
    • JPMorgan Chase downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded JPMorgan Chase from Neutral to Underperform and set a new price target of $235.00

      6/27/25 7:46:30 AM ET
      $JPM
      Major Banks
      Finance
    • TD Cowen initiated coverage on JPMorgan Chase with a new price target

      TD Cowen initiated coverage of JPMorgan Chase with a rating of Buy and set a new price target of $305.00

      5/15/25 8:12:03 AM ET
      $JPM
      Major Banks
      Finance

    $JPM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President & COO Pinto Daniel E

      4 - JPMORGAN CHASE & CO (0000019617) (Issuer)

      7/2/25 4:17:29 PM ET
      $JPM
      Major Banks
      Finance
    • Director Novakovic Phebe N was granted 129 shares, increasing direct ownership by 1% to 11,947 units (SEC Form 4)

      4 - JPMORGAN CHASE & CO (0000019617) (Issuer)

      7/2/25 4:17:25 PM ET
      $JPM
      Major Banks
      Finance
    • Director Hobson Mellody L was granted 155 shares, increasing direct ownership by 0.56% to 28,043 units (SEC Form 4)

      4 - JPMORGAN CHASE & CO (0000019617) (Issuer)

      7/2/25 4:17:21 PM ET
      $JPM
      Major Banks
      Finance

    $JPM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • JPMorganChase Announces 2025 Dodd-Frank Act Stress Test Results

      JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") announced today that it has released the results of its company-run 2025 Dodd-Frank Act Stress Test for JPMorganChase and JPMorgan Chase Bank, National Association. Information can be found on the Firm's website at www.jpmorganchase.com under Investor Relations, Events & Presentations. JPMorgan Chase & Co. (NYSE:JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders' equity as of March 31, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses

      7/1/25 4:40:00 PM ET
      $JPM
      Major Banks
      Finance
    • JPMorganChase Regulatory Capital Update

      JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") has announced updated information relating to its third quarter dividend, common share repurchase program and regulatory capital requirements. Information can be found on the Firm's Investor Relations website at jpmorganchase.com/ir/news. JPMorgan Chase & Co. (NYSE:JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders' equity as of March 31, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction proc

      7/1/25 4:40:00 PM ET
      $JPM
      Major Banks
      Finance
    • J.P. Morgan Asset Management Survey Reveals Plan Sponsors' Commitment to Proactive Retirement Strategies and Financial Wellness Programs

      83% of plan sponsors feel a strong responsibility for employees' financial well-being NEW YORK, June 25, 2025 /PRNewswire/ -- J.P. Morgan Asset Management today released its sixth U.S. defined contribution (DC) plan sponsor survey findings, highlighting a growing commitment among plan sponsors to enhancing retirement outcomes and equipping participants with essential financial tools. This year's research, Scaling what works, shaping what's next, captures insights from 750 U.S. plan sponsors, providing a comprehensive snapshot of their perspectives and actions in refining retirement offerings. Plan sponsors are increasingly expanding financial wellness initiatives and developing innovative re

      6/25/25 12:00:00 PM ET
      $JPM
      Major Banks
      Finance

    $JPM
    SEC Filings

    See more
    • SEC Form FWP filed by JP Morgan Chase & Co.

      FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

      7/7/25 9:56:16 PM ET
      $JPM
      Major Banks
      Finance
    • SEC Form FWP filed by JP Morgan Chase & Co.

      FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

      7/7/25 6:42:16 PM ET
      $JPM
      Major Banks
      Finance
    • SEC Form FWP filed by JP Morgan Chase & Co.

      FWP - JPMORGAN CHASE & CO (0000019617) (Subject)

      7/7/25 12:57:34 PM ET
      $JPM
      Major Banks
      Finance

    $JPM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Jpmorgan Chase & Co sold 14 shares and bought $51 worth of shares (14 units at $3.67) (SEC Form 4)

      4 - JPMORGAN CHASE & CO (0000019617) (Reporting)

      4/11/25 4:55:53 PM ET
      $JPM
      Major Banks
      Finance

    $JPM
    Leadership Updates

    Live Leadership Updates

    See more
    • J.P. Morgan Life Sciences Private Capital Welcomes Dashyant Dhanak, Ph.D. as Venture Partner

      NEW YORK, May 19, 2025 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital, the life sciences venture and growth equity arm within J.P. Morgan Asset Management, today announced the appointment of Dashyant (Dash) Dhanak, Ph.D., as Venture Partner. Dr. Dhanak will leverage his deep scientific and operational experience in therapeutics research and development to build and grow companies with Life Sciences Private Capital. Dr. Dhanak is a seasoned pharmaceutical research and development expert with over 30 years of experience. Most recently, Dr. Dhanak was the Chief Scienti

      5/19/25 10:00:00 AM ET
      $JPM
      Major Banks
      Finance
    • J.P. Morgan Asset Management Focuses on Generational Opportunities in Real Estate, Appointing Chad Tredway as Global Head

      New role unifies asset manager's global real estate offering and expands access to firmwide capabilities NEW YORK, May 14, 2025 /PRNewswire/ -- J.P. Morgan Asset Management is enhancing its real estate business with the appointment of Chad Tredway as Global Head of Real Estate. In this new role, he will oversee real estate operations across the Americas, Europe, and Asia Pacific, increasing the firm's global reach and ability to deliver innovative investment opportunities. Mr. Tredway has a proven track record of managing real estate assets for retail and institutional client

      5/14/25 12:00:00 PM ET
      $JPM
      Major Banks
      Finance
    • Campbell Global Announces Leadership Transition: Angie Davis to Succeed John Gilleland as CEO

      PORTLAND, Ore., May 12, 2025 /PRNewswire/ -- Campbell Global, a leader in forestland investing and management, and a vital part of J.P. Morgan Asset Management's $400 billion alternatives business, is pleased to announce a significant leadership transition. Angie Davis, currently serving as President of Campbell Global, will succeed John Gilleland as Chief Executive Officer, effective October 1. Campbell Global, a pioneer in timberland investing, has been a full-service investment advisor focusing solely on commercial forestlands and related assets. Operating in core forest in

      5/12/25 3:00:00 PM ET
      $JPM
      Major Banks
      Finance

    $JPM
    Financials

    Live finance-specific insights

    See more
    • JPMorganChase Regulatory Capital Update

      JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") has announced updated information relating to its third quarter dividend, common share repurchase program and regulatory capital requirements. Information can be found on the Firm's Investor Relations website at jpmorganchase.com/ir/news. JPMorgan Chase & Co. (NYSE:JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders' equity as of March 31, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction proc

      7/1/25 4:40:00 PM ET
      $JPM
      Major Banks
      Finance
    • JPMorganChase to Host Second-Quarter 2025 Earnings Call

      As previously announced, JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") will host a conference call to review second-quarter 2025 financial results on Tuesday, July 15, 2025 at 8:30 a.m. (ET). The results are scheduled to be released at approximately 7:00 a.m. (ET). The live audio webcast and presentation slides will be available on www.jpmorganchase.com under Investor Relations, Events & Presentations. JPMorganChase will notify the public that financial results have been issued through its social media outlet @JPMorgan and @Chase on X, and by a press release over Business Wire that will provide the link to the Firm's Investor Relations website. In addition to being avail

      6/16/25 4:27:00 PM ET
      $JPM
      Major Banks
      Finance
    • JPMorganChase Declares Preferred Stock Dividends

      JPMorgan Chase & Co. (NYSE:JPM) ("JPMorganChase" or the "Firm") has declared dividends on the outstanding shares of the Firm's Series CC preferred stock. Information can be found on the Firm's Investor Relations website at https://www.jpmorganchase.com/ir/news. JPMorgan Chase & Co. (NYSE:JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $351 billion in stockholders' equity as of March 31, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.

      6/13/25 4:35:00 PM ET
      $JPM
      Major Banks
      Finance

    $JPM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by JP Morgan Chase & Co.

      SC 13D - JPMORGAN CHASE & CO (0000019617) (Filed by)

      9/12/24 2:46:34 PM ET
      $JPM
      Major Banks
      Finance
    • Amendment: SEC Form SC 13G/A filed by JP Morgan Chase & Co.

      SC 13G/A - JPMORGAN CHASE & CO (0000019617) (Filed by)

      8/9/24 1:40:34 PM ET
      $JPM
      Major Banks
      Finance
    • SEC Form SC 13G/A filed by JP Morgan Chase & Co. (Amendment)

      SC 13G/A - JPMORGAN CHASE & CO (0000019617) (Subject)

      2/13/24 4:55:49 PM ET
      $JPM
      Major Banks
      Finance